Anti-Human HER-2 (Trastuzumab) - Dylight® 488 Biosimilar (IVMB0452)
- SKU:
- IVMB0452
- Antibody Type:
- Dylight Biosimilar
- Applications:
- IHC
- FC
- Drug Development
- Pharmacokinetics
- Disease Area:
- Cancer
Description
| Product Name: | Anti-Human HER-2 (Trastuzumab) - Dylight 488 |
| SKU: | IVMB0452 |
| Size: | 100 µg |
| Antibody Type: | Biosimilar Recombinant Human Monoclonal Antibody |
| Clone: | 4D5-8 |
| Target: | HER-2/neu |
| Isotype: | Human IgG1κ |
| Host Species: | Human |
| Reactivity: | Human |
| Applications: | FC |
| Expression Host: | HEK-293 Cells |
| FC Effector Activity: | Active |
| Synonyms: | ErbB-2, NEU, NGL, HER2, TKR1, CD340, MLN 19, HER-2/neu |
| Product Concentration: | 0.2 mg/ml |
| Excitation Laser: | Blue Laser (493 nm) |
| Immunogen: | Human epidermoid carcinoma cells (A431) over-expressing EGFR. |
| Applications and Recommended Usage: | FC The suggested concentration for Trastuzumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. |
| Antigen Distribution: | Ubiquitous expression with highest expression levels found in the kidney, skin, esophagus, and small intestine. |
| Formulation: | This DyLight 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. |
| Specificity: | This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Trastuzumab. Clone 4D5-8 recognizes human erbB-2. This product is for research use only. |
| Additional Applications Reported In Literature: | IHC |
| Additional Reported Applications For Relevant Conjugates: | CyTOFELISA |
Trastuzumab is a monoclonal antibody targeting HER2, a 185 kDa transmembrane glycoprotein that contains an extracellular domain and intracellular tyrosine kinase activity. When it is functioning normally, the HER2 pathway supports cell growth and division. On the other hand, the over expression of HER2 propels cell growth beyond its typical range. This overexpression is associated with some cancers, namely breast and stomach, in which the HER2 protein can be expressed up to 100 times more than in typical cells. Trastuzumab induces an immune-mediated response that triggers the internalization and downregulation of HER2 making it an excellent target for immunotherapy. Several clinical studies are under way which show that anti-HER-2/neu antibodies inhibit the growth and proliferation of these tumor cells In vitro as well as In vivo.
| Regulatory Status: | Research Use Only (RUO). Non-Therapeutic. |
| Storage and Handling: | This DyLight 488 conjugate is stable when stored at 2-8°C.Do not freeze. |
| Research Area: | Biosimilars |
Related Products
Anti-Human EGFR (Cetuximab) - Dylight® 488 Biosimilar (IVMB0515)
Anti-Human OX40L (Oxelumab) - Dylight® 488 Biosimilar (IVMB0440)
Anti-Human CD52 (Alemtuzumab) - Dylight® 488 Biosimilar (IVMB0476)
Anti-Human CD20 (Rituximab) - Dylight® 488 Biosimilar (IVMB0530)
